Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that its New Drug Submission for CIP-ISOTRETINOIN, a novel, patented formulation of the acne medication...

Toronto Stock Exchange Symbol: DND - Company receives US$1.0 million milestone - - Company also files New Drug Submission with Health Canada - MISSISSAUGA, ON, Dec. 21, 2011 /CNW/ - Cipher...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has submitted an amendment to its pending New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three months ended September 30, 2011 ("Q3 2011"). Q3 2011 Summary Cipher's U.S. marketing...

- Third quarter financial results to be released October 26, 2011 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 19, 2011 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a distribution and supply agreement with Medical Futures Inc. ("Medical Futures"), a...

Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Rodman & Renshaw Annual Global Investment Conference, which...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that Health Canada has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2011 ("Q2 2011"). Q2 2011 Summary Licensed the U.S....

- Second quarter financial results to be released July 26, 2011 - Toronto Stock Exchange Symbol: DND MISSISSAUGA,ON, July 7, 2011 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...